Please login to the form below

Not currently logged in
Email:
Password:

KRAS

This page shows the latest KRAS news and features for those working in and with pharma, biotech and healthcare.

Amgen buys BeiGene stake for $2.7bn to aid push into China

Amgen buys BeiGene stake for $2.7bn to aid push into China

Included in that part of the deal however is Amgen’s much-anticipated KRAS inhibitor  AMG 510, and its bispecific antibody pipeline featuring anti-BCMA candidate  AMG 420.

Latest news

  • Amgen reveals more data on KRAS drug Amgen reveals more data on KRAS drug

    It is estimated that around 14% of NSCLC adenocarcinoma patients and roughly 5% of colorectal cancer patients have the KRAS G12C mutation. ... Amgen is leading the field among companies developing inhibitors of KRAS, an oncogene that is implicated in

  • Boehringer bolsters KRAS push with $720m Lupin deal Boehringer bolsters KRAS push with $720m Lupin deal

    the hope of providing “more effective and durable responses” in KRAS-driven tumours. ... We believe this collaboration will significantly strengthen our KRAS programme,” said Boehringer’s head of cancer research Norbert Kraut.

  • Boehringer Ingelheim forms ‘virtual research’ alliance with MD Anderson Boehringer Ingelheim forms ‘virtual research’ alliance with MD Anderson

    According to Boehringer, the new centre will focus on developing new cancer treatments, with particular emphasis on investigating KRAS inhibition concepts. ... Mutations in the KRAS pathway have been recognised for decades as a key part of oncology

  • Has Amgen cracked KRAS? First clinical data says maybe Has Amgen cracked KRAS? First clinical data says maybe

    It is estimated that around 14% of NSCLC adenocarcinoma patients and roughly 5% of colorectal cancer patients have the KRAS G12C mutation. ... The KRAS G12C mutation has emerged as a clear front-runner among the various targets for pharmacological

  • So far so good for Amgen's much-anticipated KRAS inhibitor So far so good for Amgen's much-anticipated KRAS inhibitor

    Promise to hit previously 'undruggable' target. Amgen has the first clinical data for its inhibitor of KRAS, a cancer target long though to be almost undruggable despite its promise. ... Amgen is in a race with Mirati Therapeutics to bring a KRAS G12C

More from news
Approximately 4 fully matching, plus 23 partially matching documents found.

Latest Intelligence

  • Encouraging signs in biomarker R&D Encouraging signs in biomarker R&D

    The questions being asked are, what does an individual’s mutational profile look like, and do we have a drug to treat it; ie, do they have EGFR mutations, KRAS or

  • Interview: AstraZeneca's Susan Galbraith Interview: AstraZeneca's Susan Galbraith

    This includes people with NSCLC who have a mutated KRAS gene - an area where no specific treatment option exists. ... With selumetinib you've now got that plus another 20-25 per cent of NSCLC cases - people with the KRAS mutation.”.

  • Pharma deals during September 2012 Pharma deals during September 2012

    advanced KRAS; a wild-type metastatic colorectal cancer (mCRC). ... 665. Symphogen / Merck KGaA. Product licence. Sym004 for advanced KRAS; a wild-type metastatic colorectal cancer (mCRC) (phase I /II).

More from intelligence
Approximately 0 fully matching, plus 3 partially matching documents found.

Latest appointments

More from appointments
Approximately 0 fully matching, plus 1 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Anatomy Health

We are a health information design consultancy focused on developing simple, accessible and inclusive patient communications. From evaluating existing patient...

Latest intelligence

RWE Blog 3: Is real-world evidence the holy grail
We began our four-blog series by evaluating the role of real-world data (RWD) and real-world-evidence (RWE) in Real-world challenges and real-world data, and understanding the payer's perspective, in Payers use...
What do Healthcare Professionals think about the inclusion of remote selling techniques?
Evolving to a digitally focused pharma / healthcare company - an organisational roadmap...
Drug pricing and competition
Strengthening business competition and reducing anti-competitive practices
How the CMA is tackling high prices for essential drugs...

Infographics